Breast Cancer

, Volume 12, Issue 2, pp 99–103 | Cite as

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma

  • Hiroji Iwata
  • Seigo Nakamura
  • Masakazu Toi
  • Eisei Shin
  • Norikazu Masuda
  • Shinji Ohno
  • Yuichi Takatsuka
  • Kazufumi Hisamatsu
  • Kosuke Yamazaki
  • Mikihiro Kusama
  • Hiroshi Kaise
  • Yasuyuki Sato
  • Katsumasa Kuroi
  • Futoshi Akiyama
  • Hitoshi Tsuda
  • Masafumi Kurosumi
Workshop

Abstract

Purpose

A single-arm phase II multicenter trial of the combination of cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) followed by docetaxel as neoadjuvant chemotherapy is being conducted by the Japan Breast Cancer Research Group. This report describes an interim analysis of the clinical response and safety of 79 patients who finished preoperative chemotherapy and surgery.

Patients and Methods

Patients with operable breast cancer received C at 500 mg/m2, E at 100 mg/m2, and F at 500 mg/m2 every 21 days for 4 cycles followed by docetaxel at 75 mg/m2 every 21 days for 4 cycles.

Results

Of the 79 patients evaluable for analysis the median age was 46 years (28–59). and 61 patients (77.2%) had T2 tumors. A total of 312 of 316 (98.7%) cycles of CEF and 296 of 312 (94.9%) cycles of docetaxel were administered. Average total cumulative dose was 92% and 95% for CEF and docetaxel, respectively. The rate and grade of edema, neuropathy, arthralgia and myalgia were higher with docetaxel than with CEF. The overall clinical response rate was 70.9%. Breast conserving surgery was performed in 31 of 42 patients (73.8%) with a base-line tumor size of more than 3 cm.

Conclusions

Interim data suggest that CEF followed by docetaxel is an active and tolerable neoadjuvant chemotherapy regimen. A final analysis is planned for 2005.

Key words

Preoperative chemotherapy CEF Docetaxel 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Fisher B, Bryant J, Wolmark N, Mamounas E, Brown Ann, Fisher ER, Wicerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoen JL, Lees AW, Dimitrov NV, Bear HD: Effect of prospective chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672–2685, 1998.PubMedGoogle Scholar
  2. 2).
    Van der Huge JA, Van der Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L; Cooperating investigators: Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902.J Clin Oncol 19:4224–4237, 2001.Google Scholar
  3. 3).
    Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchhols TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Eva Singletary S: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorabicine-based neoadjuvant chemotherapy.J Clin Oncol 17:460–469, 1999.PubMedGoogle Scholar
  4. 4).
    Scholl SM, Fourqeet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Louve M, Beuzeboc P: Neoadjuvant versus adjuvant chemotherapy in premonopausal patients with tumours considered too large for breast conserving surgery preliminary results of a randomized trial: S6.Eur J Cancer 30:645–652, 1994.CrossRefGoogle Scholar
  5. 5).
    Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Deblet M, Dihuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow up. Institut Bergoni Bordeaux Groupe Sein (IBBGS).Ann Oncol 10:47–52, 1999.PubMedCrossRefGoogle Scholar
  6. 6).
    Von Minckwitz G, Costa SD, Raab G, Blohmer LU, Eidtmann H, Hilfrich L, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufman M: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimilating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.J Clin Oncol 17:460–469, 1999.Google Scholar
  7. 7).
    Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent cancer.British J Cancer 73:210–216, 1996.Google Scholar
  8. 8).
    Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O; Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.Clin Breast Cancer 2:S69–74, 2002.CrossRefGoogle Scholar
  9. 9).
    Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol 21:4165–4174, 2003.PubMedCrossRefGoogle Scholar
  10. 10).
    Commitee for Production of Histopathological Criteria, Japanese Breast Cancer Society, Chairman: Kurosumi M, Members: Akiyama F, Iwase T, Motomura K, Okazaki M, and Tsuda H: Histopathological Criteria for Assessment of Therapeutic Response in Breast Cancer.Breast Cancer 8:1–2, 2001.CrossRefGoogle Scholar
  11. 11).
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, Oosterom AT, Christian NC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst 92:205–216, 2000.PubMedCrossRefGoogle Scholar
  12. 12).
    Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.Oncology 11 (suppl 8):15–18, 1997.PubMedGoogle Scholar
  13. 13).
    Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard J-L, Body G, Dauplat J, Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a hig pathological response and breast-cobservation rate.British J Cancer 88:1339–1345, 2003.CrossRefGoogle Scholar
  14. 14).
    Piccart MJ, Klijin J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for research and treatment of cancer investigational drug branch for breast cancer.J Clin Oncol 15:3149–3155, 1997.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2005

Authors and Affiliations

  • Hiroji Iwata
    • 1
    • 2
  • Seigo Nakamura
    • 2
  • Masakazu Toi
    • 2
  • Eisei Shin
    • 2
  • Norikazu Masuda
    • 2
  • Shinji Ohno
    • 2
  • Yuichi Takatsuka
    • 2
  • Kazufumi Hisamatsu
    • 2
  • Kosuke Yamazaki
    • 2
  • Mikihiro Kusama
    • 2
  • Hiroshi Kaise
    • 2
  • Yasuyuki Sato
    • 2
  • Katsumasa Kuroi
    • 2
  • Futoshi Akiyama
    • 2
  • Hitoshi Tsuda
    • 2
  • Masafumi Kurosumi
    • 2
  1. 1.Aichi Cancer Center Hospital Breast SurgeryNagoyaJapan
  2. 2.Japan Breast Cancer Research Group (JBCRG)Japan

Personalised recommendations